History of Cipla Ltd.
1935
- The Comp. was Incorporated at Mumbai.
1979
- The Comp. acquired a plot of land from MIDC at Patalganga in Kulaba district of Maharashtra State about 55 kms. from Mumbai.
- 18,773 Bonus equity shares issued in proportion 1:1.
1984
- The name of Comp. was changed from The Chemical Industrial & Pharmaceutical Laboratories Ltd., to the present one with effect from 20th July.
1985
- 37,546 Bonus equity shares issued in proportion 1:1 in January 1986.
1986
- During August, the Comp. obtained the consent of Controller of Capital Issues to issue 3,00,000-15% secured non-convertible redeemable debentures of Rs 100 each aggregating to Rs 300 lakhs by private placement. The entire issue was subscribed by public financial institutions. They are redeemable at a premium of 5% during 1993-94.
1987
- The Comp. launched several new products viz., Asthalin & Beclate Rotahalers/Rotacaps-dry powder inhalation devices for asthma, presolar capsules - the first synergistic combination of beta blocker & a sustained release calcium channel blocker for hypertension, Restyl tablets - the first anxiolytic-cum-anti depressant, Theo-Asthalin SR tablets - the first sustained release combination of two widely used bronchodilators, bromolin dry syrup & bromolin-250 capsules - antibiotic-cum-mucolytic agents, dilgard tablets - a new calcium channel blocker for angina, ibugesic plus suspension - a non steroidal anti inflammatory & anti-pyretic analgesic for paediatric use.
- 75,092 Bonus equity shares issued in proportion 1:1.
1989
- The latest drugs introduced during the year were [is] Ciplox tablets [250 and 500 mg.s] & infusion [50 & 100 ml.s], a broad spectrum fluoroquinolone antibacterial for severe infections, [iis] cefadur capsules [250 and 500 mg.s] & syrup [30 ml.s], a cephalosporin antibiotic, [iiis] Ulcimax tablets [20 and 40 mg.s], a long-acting H2 antogonist for peptic ulcers & [ivs] theoped syrup, a paediatric bronchodilator. Sales in the Company `PROTEC' division exceeded Rs 5.50 crores for second year of its operations.
1990
- The Comp. launched several new products viz., Aerocort inhaler, an anti-inflammatory bronchodilator, Norflox eye/ear drops - a broad spectrum fluoroquinolone antibacterial, Pirox Gel - the first topical piroxicam formulation in the country, Cofenac tablets - an anti-infammatory analgesic, Kinetal 400 tablets - a multi-functional drug for vascular insufficiency, Novaclox Ped tablets - a dispensible combination antibiotics, Terfed tablets & Suspension - a new non-sedative antihistamine, Depryl tablets - a broad - spectrum antidepressant, Asthalin Respirator Solution - a bronchodilator for pressure ventilation in acute asthma. The Comp. spent Rs 4.22 crores on R&D & Rs 8.09 crores on modernisation & expansion of plant and machinery.
1991
- The new products launched during the year were lomac capsules - a new antiulcerant, cromal inhaler - the first optimum - dose inhalant prophylactic for asthma, ciplox eye drops - the total bactericide for ocular infections, etosid injection - the first injection of indigenously manufactured etoposide for cancer therapy, proflox tablets - a key fluoroquinolone antibiotic & vasopril tablets - an ACE inhibitor for long-term management of hypertension. The research and development wing of Comp. developed during the y ar felodipine - the latest anti-hypertensive drug, selegilinje - a new bulk drug for the treatment of Parkinson disease, cetirizine HCI - an anti-histamine drug & nimodipine - a cerebral vasodilator. Work on the anti-AIDS drug AZT reached an advance stage of development. The research & development wing also developed anthelmintics oxfendazole and oribendazole, two veterinary products for exports.
- In May, 6,000 equity shares offered at par as rights to pref. shareholders in prop. 1:1. Only 5,216 shares taken up. Allotment of 5 equity shares pending.
1992
- Some of new products introduded were Zidovir capsules an antiretroviral for HIV injection, Cipril tablets for hypertension, Optipres eyedrops for glaucoma patients, Felogard for hypertension, Nodine, a non-narcotic analgesic, etc.
- In compliance with the provisions of Companies Act, 1956, the Company redeemed its 6,000 preference shares of Rs 100 each as on 30th September.
- Pref. shares redeemed on 30.9.92, 1,55,395 bonus equity shares issued in prop. 1:1.
1994
- New products introduced were - Beclate Aquanase - a major advancement in allergic rhinitis; Cytoplatin - an anticancer agent; Forcan - an antifungal; Imusporin - an immunosuppressant in organ transplantation; Kelfer - an iron chelator for thalassaemia; Lanzol - a proton pump inhibitor; Nuzac - an antidepresant; Odirox - a macrolide antibiotic and Qinarsol - for chloroquin-resistant malaria.
- Equity shares subdivided 155,39,500. Equity shares allotted shares issued in prop. 1:5.
- The Company manufacturing unit at Kurkumbh, which was commissioned in April. The second phase of expansion of location was under way and this was to provide specialised facilities for manufacture of new chemical entites.
1995
- Effective 4th July, the Comp. was forced to declare a lock-out as some of workmen at the Vikhroli Unit resorted to indiscipline. The Company initiated steps to mitigate the impact it could have on production.
- New products introduced were - Acivir - antivirus herpes, Anlopres - antivirus herpes, Anlopres - Calcium channel blocker in hypertension and angina, Anlopres AT - a combination antihypertensive, Budecort 200 - a higher strength corticosterord in bronchial asthma, Budenase AQ - a corticosteroid protection in allergic rhinitis, cronal - a nast cell stabiliser in allergic conjunctivitis, cytonid - a antiandrogenic agent in prostate cancer, Norflox - an antidiarrhoeal in diarrhoea of mixed origin, optipes S - betaxocol eye drops, profenac - anti-inflammatory eye drops, Terfed D - a combination antihistamine & decongestant, Trivedon 20 - used in ischaemic heart disease.
- A new chemical entity, candocuronium iodide - a neuromuscular blocking agent was manufactured, other new bulk drugs manufactured include: Acyelovir - antiviral, Amlodipine besylate - antihypertensive and antianginal, Febantel - veterinary anthelmintic, Flutamide - antiandrogen, Flutivcasone dipropionate - a corticosteriod, zenprolide acetate - GMRH analogue.
- 13,43,383 rights equity shares issued [Prem. Rs. 60/-s]. However, the Rights issue was underwritten.
1996
- The products launched during the year were Azee [azithromycin capsuless] - a new macrolide antibiotic; Budecort [budesonide rotacapss] - dry powder inhaled corticosteriod therapy for asthama; Cipril H [lisionopril + hydrochlorothiazide tabletss] - a combination antihypertensive; Ciplox TZ [ciprofloxacin + tinidazole tabletss] - the combination bactericide for aerobic/anaerobic infections; Entosec [secnidazole tabletss] - single dose therapy for amoebiasis/trichomoniasis; Fincar [finasterid tabletss] - for beign prostatic hyperphasia; Metolar [metaprolol injections] - beta-blocker protection for post myocardial infarction and Zoflut [fluticasone propionate creams] - a new topical corticosteroid.
1997
- The products introduced during the year were; Alerid-D - an antihistamine & decongestant for cold & congestion, Amlopres L - a tablet for hypertension, Apuatears - an eye drop, Azee 1000 - a single dose for STDs, Budecort Respules - neubulised corticosteroid therapy for asthma, Dilgard XL - a diltiazem, Glumet - tablet for obese diabetics, Glygard - tablet for abese diabetics, Glygard - tablet for diabetics, Ipranase AQ [ipratropium nasal sprays] - an anticholinergic therapy for rhinorrhoea, Ocutim [an eye drops] - a glaucoma therapy in acquafilm formulation, Osteifos 10 - tablet for osteoporosis, Prolyte Fizz - a rehydration effervescent tablet, Pylokit - an advanced H pylori kit, Risnia - an a typical antipsychotic, Stavir - an antiretroviral for AIDS, Synclar 250 - an advanced macrolide antibiotic, Theoday - a tablet for asthma, Zoflut Lotion - a topical corticosteroid.
- The bulk division of Comp. had taken up, the development and manufacture of some new drugs viz., budesonide - antiasthmatic corticosteroid, carvedilol - alpha/beta blocker, ebastine - antihistamine, formoterol fumarate - antiasthmatic, meloxicam - for osteroarthritis & rheumatoid arthritis, moclobemide - antidepressant, mometasome furoate - antiflammatory corticosteroid, pantorazole sodium sesquihydrate - antiulcerant, sildenafil citrate - erectile dysfuncion.
- The Comp. has developed a form-fill-seal equipment for first time in India, for manufacture of sterile formulations. This was commissioned at Vikhroli factory & is working to its full capacity. Additional capacities were set up at Kurkumbh for manufacture of effervescent tablets, soft gel capsules & injectable formulations. The Comp. has incurred a capital expenditure of Rs 22.73 crores during the year.
- The Rs. 3.69 billion Cipla has finalised a marketing joint venture with Australia-based Genpharm, as part of its strategy to consolidate its global presence.
- Pharmaceutical major Cipla Ltd grabbed the attention of traders at the Mumbai Stock Exchange [BSEs] on December 26 after a large block of about 75,000 shares of Comp. valued at little over Rs 5 crore changed hands.
- The Rs.369-crore Cipla Ltd has entered into a souring arrangement with US-based Geneva Pharmaceuticals, a wholly-owned subsidiary of Swiss multinational Ciba, for a range of generic drugs.
1998
- Pharmaceutical companies, Cipla & Wockhardt, will be seeking shareholders' approval for a proposed share buyback at their forthcoming annual general meetings.
- In a notice to shareholders, Cipla has proposed introduction of new article, Article 64 A, in the Articles of Association of Comp. to enable the Comp. to purchase & re-issue any of its shares. The existing Article 64 prohibits the Comp. from buying its own shares and applying any of its funds for purchase of any shares of the company.
- The share price of Cipla Ltd, the leading pharmaceutical company scaled a new peak of Rs 920 on the Mumbai Stock Exchange on Sept 29 following fresh bull charge. The scrip opened at Rs 900 & shot up to Rs 920 during mid-session & closed at Rs 884 following hectic trading activities.
1999
- Ranbaxy & Cipla, have entered into a strategic partnership to jointly market a select basket of drugs. The alliance will bring forth their strengths in the strongly emerging cardiovascular & perennial anti-infectives market.
- As a first step, the two molecules being jointly launched are Carvedilol, a new generation anti-hypertensive & Cefpodoxime Proxetil, an advanced third generation oral cephalosporin.
- The Rs 541-crore Cipla has forged a strategic alliance with the UK-based Neolab for marketing a range of generic drugs. The alliance, while improving the Indian company access to the multi-billion dollar European market for off-patent drugs, will also see Cipla rake in royalties on sales of products covered under the deal. - Cipla latest tie-up in the international market comes close on the heels of company strategic partnership with the Delhi-based Ranbaxy Laboratories for a select basket of drugs. - The Mumbai-based Cipla is working on abbreviated new drug applications [ANDAss] in collaboration with international generics firms for a range of products like flutamide [for advanced prostatic cancers] and felodipine, for hypertension.
2000
- Cipla & Ranbaxy Laboratories have expanded an existing partnership by adding one more new drug in their co-marketing arrangement.
2001
- Cipla has tied up with the US-based Zenith Goldline & United Research Labs for marketing Flutamide, an oncology drug, and Felodipine, a cardiovascular drug, in the US & European markets.
- Domestic pharma giant, Cipla, has despatched its first free consignment of anti-AIDS drug, `Nevirapine', to the Indian Government for distribution under the public health system.
2002
-Reduces the price of its anti-HIV medicines such as Stavir, Lamivir, Nevimune, Dinex, Indivan, Triomune, Efavir & Duovir
-Revokes interim dividend of Rs 5 per share on face value of Rs 10 per share for FY 2001-02
-Company included in the World Health Organisation [WHO'ss] list of HIV-related products
-Chairman & Managing Director YK Hamied was presented with the lifetime contribution award for excellence in the pharmaceutical industry by Union chemicals and fertilisers minister SS Dhindsa
-Resigns from Indian Pharmaceutical Alliance [IPAs] over Patents Bill
2003
-Applies its requisiton for Abbreviated New Drug Application [ANDAs] with US regulators for a post-menopausal drug
-National Pharmaceutical Pricing Authority [NPPAs] issues notices to Cipla along with Ranbaxy for overcharging the products
-Completes research studies on three Anti-HIV Drugs
-Registers Stavudine, Nevirapine, other anti-AIDS products in South Africa
2004
-Signs long-term agreement with Morton Grove Pharmaceuticals Inc [MGPs] of Illinois, US, for product launch in the US market
-Avesthagen forges alliance with Cipla
-Cipla has joined a global initiative taken up by Vatican in collaboration with global generic pharmaceutical manufacturers & the International Federation of Catholic Pharmacies & Academics to float CUMVIVIUM
-Cipla join hands with Pentech Pharma
-Indian pharma major Cipla, a pioneer in supplying cheap generic AIDS drugs in Africa, has patented its three-in-one combination tablet Triomune in South Africa
-Cipla introduces 'Duova' to fight chronic obstructive pulmonary disease
- Launches a new treatment for arthritis in technical collaboration with California-based Cymbiotics Inc.
2007
- Cipla unveils anti-malaria global initiative.
2008
-Cipla Ltd has appointed Mr. Pankaj Patel as a Director in casual vacancy with effect from March 05, 2008.
